Literature DB >> 33523562

CRKL promotes hepatocarcinoma through enhancing glucose metabolism of cancer cells via activating PI3K/Akt.

Chunmei Guo1, Chao Gao1, Xinxin Lv1, Dongting Zhao1, Frederick T Greenaway2, Lihong Hao3, Yuxiang Tian4, Shuqing Liu4, Ming-Zhong Sun1.   

Abstract

Abnormal glucose metabolism may contribute to cancer progression. As a member of the CRK (v-crk sarcoma virus CT10 oncogene homologue) adapter protein family, CRKL (CRK-like) associated with the development and progression of various tumours. However, the exact role and underlying mechanism of CRKL on energy metabolism remain unknown. In this study, we investigated the effect of CRKL on glucose metabolism of hepatocarcinoma cells. CRKL and PI3K were found to be overexpressed in both hepatocarcinoma cells and tissues; meanwhile, CRKL up-regulation was positively correlated with PI3K up-regulation. Functional investigations revealed that CRKL overexpression promoted glucose uptake, lactate production and glycogen synthesis of hepatocarcinoma cells by up-regulating glucose transporters 1 (GLUT1), hexokinase II (HKII) expression and down-regulating glycogen synthase kinase 3β (GSK3β) expression. Mechanistically, CRKL promoted glucose metabolism of hepatocarcinoma cells via enhancing the CRKL-PI3K/Akt-GLUT1/HKII-glucose uptake, CRKL-PI3K/Akt-HKII-glucose-lactate production and CRKL-PI3K/Akt-Gsk3β-glycogen synthesis. We demonstrate CRKL facilitates HCC malignancy via enhancing glucose uptake, lactate production and glycogen synthesis through PI3K/Akt pathway. It provides interesting fundamental clues to CRKL-related carcinogenesis through glucose metabolism and offers novel therapeutic strategies for hepatocarcinoma.
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Entities:  

Keywords:  CRKL; PI3K/Akt pathway; glucose metabolism; hepatocarcinoma

Year:  2021        PMID: 33523562      PMCID: PMC7933966          DOI: 10.1111/jcmm.16303

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


  51 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

Review 2.  Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

Authors:  Nissim Hay
Journal:  Nat Rev Cancer       Date:  2016-09-16       Impact factor: 60.716

Review 3.  Warburg effect and its role in tumourigenesis.

Authors:  Maphuti T Lebelo; Anna M Joubert; Michelle H Visagie
Journal:  Arch Pharm Res       Date:  2019-08-31       Impact factor: 4.946

Review 4.  The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes.

Authors:  Arnold J Levine; Anna M Puzio-Kuter
Journal:  Science       Date:  2010-12-03       Impact factor: 47.728

Review 5.  The role of CT10 regulation of kinase-like in cancer.

Authors:  Chunmei Guo; Shuqing Liu; Ming-Zhong Sun
Journal:  Future Oncol       Date:  2014-12       Impact factor: 3.404

6.  Fibroblast Growth Requires CT10 Regulator of Kinase (Crk) and Crk-like (CrkL).

Authors:  Taeju Park; Mateusz Koptyra; Tom Curran
Journal:  J Biol Chem       Date:  2016-11-02       Impact factor: 5.157

7.  Emerging roles for crk in human cancer.

Authors:  Ganapathy Sriram; Raymond B Birge
Journal:  Genes Cancer       Date:  2010-11

Review 8.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

9.  Flavonoid GL-V9 induces apoptosis and inhibits glycolysis of breast cancer via disrupting GSK-3β-modulated mitochondrial binding of HKII.

Authors:  Yongjian Guo; Libin Wei; Yuxin Zhou; Na Lu; Xiaoqing Tang; Zhiyu Li; Xiaotang Wang
Journal:  Free Radic Biol Med       Date:  2019-10-24       Impact factor: 7.376

Review 10.  Dysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in Cancer Cells

Authors:  Casterland Marbaniang; Lakhan Kma
Journal:  Asian Pac J Cancer Prev       Date:  2018-09-26
View more
  1 in total

1.  CRKL promotes hepatocarcinoma through enhancing glucose metabolism of cancer cells via activating PI3K/Akt.

Authors:  Chunmei Guo; Chao Gao; Xinxin Lv; Dongting Zhao; Frederick T Greenaway; Lihong Hao; Yuxiang Tian; Shuqing Liu; Ming-Zhong Sun
Journal:  J Cell Mol Med       Date:  2021-02-01       Impact factor: 5.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.